On this page
Quick Reference
Overview and Recommendations
Background
- •Tumor lysis syndrome (TLS) is an oncologic emergency caused by the rapid release of intracellular contents, potassium, phosphate, uric acid, and purine metabolites, into the bloodstream following massive tumor cell death, overwhelming normal homeostatic mechanisms and leading to life-threatening metabolic derangements.
- •TLS occurs in approximately 10.5% of hospitalized patients with hematologic malignancies, with the highest risk in high-grade lymphomas like (where up to 56% of children present with TLS at diagnosis) and acute leukemias such as AML (incidence 23.1% during induction). The emergence of potent targeted therapies, including , , bispecific T-cell engagers, and CAR-T cells, has expanded the at-risk population beyond traditional chemotherapy.
- •The paradigmatic framework for classification is the , which distinguishes laboratory TLS (≥2 metabolic abnormalities: uric acid ≥8 mg/dL, potassium ≥6.0 mEq/L, phosphate ≥4.5 mg/dL, corrected calcium ≤7 mg/dL, within 3 days before to 7 days after therapy) from clinical TLS (laboratory criteria plus organ dysfunction: acute kidney injury, arrhythmia, seizure, or death). Clinical TLS carries substantially higher mortality, with rates exceeding 50% in some series.
- •The pathophysiologic axis is driven by hyperuricemia causing urate crystal nephropathy, hyperphosphatemia leading to calcium-phosphate precipitation in renal tubules, and hyperkalemia triggering cardiac arrhythmias, all of which can be prevented or mitigated by early recognition and aggressive intervention.
- •Spontaneous TLS (occurring before any therapy) is rare but reported in high-burden hematologic malignancies and solid tumors, where it carries a 74% mortality in elderly patients. The syndrome is also increasingly recognized with newer agents; for example, the MCL-1 inhibitor AZD5991 caused a fatal TLS event, and the p53-MDM2 inhibitor siremadlin triggered TLS in 22 patients across dosing cohorts.
- •The paradigm of prevention has shifted from universal hydration and allopurinol to risk-stratified prophylaxis: low-risk patients receive hydration alone, intermediate-risk receive hydration plus a xanthine oxidase inhibitor ( 300-600 mg/day or 40-80 mg/day), and high-risk patients receive upfront (0.2 mg/kg or fixed 1.5-3 mg dose) to rapidly reduce existing uric acid.
Evaluation
- •Suspect TLS in any patient initiating cytoreductive therapy for a high-risk hematologic malignancy (e.g., Burkitt lymphoma, acute lymphoblastic leukemia, AML with high blast count) or any patient receiving venetoclax, especially during the ramp-up phase. Also consider spontaneous TLS in patients with bulky or rapidly growing tumors before treatment.
- •Ask about baseline renal function, history of gout or hyperuricemia, tumor burden (e.g., bulky adenopathy, hepatosplenomegaly), and any prior episodes of TLS. Review the medication list for diuretics, ACE inhibitors, or NSAIDs that may worsen renal function.
- •Examine for signs of fluid overload (peripheral edema, pulmonary crackles), signs of hyperkalemia (muscle weakness, areflexia), signs of hypocalcemia (Chvostek sign, Trousseau sign, tetany), and cardiac arrhythmias (palpitations, irregular pulse, ECG changes).
- •Order baseline labs before any therapy: serum uric acid, potassium, phosphate, calcium (corrected for albumin), creatinine, BUN, and lactate dehydrogenase (LDH). LDH serves as a surrogate for tumor burden and a rise often precedes the classic metabolic abnormalities.
- •After starting therapy, repeat labs every 6-12 hours for the first 48-72 hours in high-risk patients, and every 8-12 hours in intermediate-risk patients. Low-risk patients can be monitored daily. The most common cause of missed TLS is failure to monitor frequently enough during this window.
- •Apply the Cairo-Bishop criteria to diagnose laboratory TLS: two or more metabolic abnormalities (uric acid ≥8 mg/dL or 25% increase from baseline, potassium ≥6.0 mEq/L or 25% increase, phosphate ≥4.5 mg/dL in adults or 25% increase, corrected calcium ≤7 mg/dL or 25% decrease) occurring within 3 days before to 7 days after initiation of therapy.
- •If laboratory TLS is present, assess for clinical TLS by checking for acute kidney injury (creatinine ≥1.5× upper limit of normal or ≥25% increase), cardiac arrhythmia (ECG, continuous monitoring), seizure, or sudden death. Clinical TLS requires immediate ICU admission.
- •Also consider pseudohyperkalemia in patients with extremely high white blood cell or platelet counts (>50,000/μL or >1,000,000/μL, respectively), draw a plasma potassium level to confirm before treating.
- •Obtain an ECG immediately if potassium >6.0 mEq/L or if the patient reports palpitations; look for peaked T waves, widened QRS, prolonged QT (from hypocalcemia), or sine-wave pattern.
- •Additional diagnostic tests: urine analysis for uric acid crystals, phosphate crystals, and specific gravity; renal ultrasound if AKI is present to rule out obstructive causes; continuous cardiac monitoring for all patients with clinical TLS.
- •In patients with solid tumors, especially elderly with hepatic metastases, a serum phosphate >6.0 mg/dL at presentation discriminates mortality risk (AUC 0.865) and should prompt early nephrology consultation.
- •Finally, consider alternative causes of the metabolic derangements: tumor lysis from other causes (e.g., radiation therapy, corticosteroids, spontaneous in high-burden disease), or other conditions causing hyperkalemia (e.g., renal failure, potassium-sparing diuretics) or hyperuricemia (e.g., tumor necrosis, hemolysis).
Management
- •Initiate aggressive intravenous hydration with a balanced crystalloid solution (e.g., Lactated Ringer's or Plasma-Lyte) at 2-3 L/m²/day in adults, equivalent to approximately 200 mL/hour, adjusted for cardiac and renal function. Target urine output ≥2 mL/kg/hour.
- •For hyperuricemia in established TLS, administer rasburicase as the drug of choice: either 0.2 mg/kg intravenously once daily for up to 5 days, or a fixed single dose of 1.5-3 mg (which is often sufficient). Rasburicase rapidly converts uric acid to allantoin; do not use allopurinol for established hyperuricemia as it does not reduce existing uric acid.
- •For prophylaxis of hyperuricemia in intermediate-risk patients, start allopurinol 300-600 mg/day orally (10 mg/kg/day in children divided every 8 hours, maximum 800 mg/day) 24-48 hours before therapy. Alternatively, febuxostat 40-80 mg/day can be used and may be preferred in patients with allopurinol intolerance or mild renal impairment.
- •For hyperkalemia with potassium >6.0 mEq/L or any ECG changes (peaked T waves, widened QRS), administer emergency treatment: calcium gluconate 10% solution, 10-20 mL intravenously over 2-5 minutes to stabilize the cardiac membrane, followed by regular insulin 10 units intravenously plus 50% dextrose 25 g intravenously to shift potassium intracellularly. Nebulized albuterol 10-20 mg can be added for additional shift.
- •After emergency shift therapy, remove potassium definitively: use loop diuretics (e.g., furosemide 20-40 mg IV) if renal function is adequate, or initiate renal replacement therapy if refractory or if the patient has oliguric AKI.
- •For hyperphosphatemia, administer oral phosphate binders such as calcium carbonate 500-1000 mg with meals or sevelamer 800-1600 mg three times daily to limit gastrointestinal absorption. However, the mainstay of treatment is aggressive hydration and diuresis; severe hyperphosphatemia may require dialysis.
- •For hypocalcemia, treat only if symptomatic (tetany, seizures, prolonged QT interval). If treatment is needed, give calcium gluconate 10% solution, 10-20 mL intravenously cautiously, with close monitoring of the calcium-phosphate product to avoid worsening calcium-phosphate precipitation.
- •For acute kidney injury, initiate renal replacement therapy (RRT) early, the threshold for RRT is lower in TLS than in other settings due to the risk of rapid, unpredictable electrolyte spikes. Continuous RRT (CRRT) is preferred over intermittent hemodialysis in hemodynamically unstable patients.
- •Indications for RRT: severe hyperkalemia refractory to medical therapy (K persistently >6.0), severe hyperphosphatemia (phosphate >6.0 mg/dL), oliguric AKI, or fluid overload unresponsive to diuretics. Consult nephrology early.
- •Avoid calcium administration for asymptomatic hypocalcemia, as it may precipitate calcium phosphate crystals in the renal tubules and worsen AKI.
- •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they can exacerbate hyperkalemia-induced cardiac depression, though evidence is limited; use beta-blockers or other agents if needed for rate control.
- •Do not rely on allopurinol alone for established hyperuricemia; it does not reduce existing uric acid and may take days to lower levels.
- •Provide patient education: instruct patients to maintain high oral fluid intake if not contraindicated, and to report symptoms of TLS (nausea, muscle cramps, palpitations, decreased urine output, fatigue) immediately, especially during venetoclax ramp-up at home.
- •Refer to ICU for any patient with clinical TLS (laboratory TLS plus organ dysfunction). For high-risk patients without clinical TLS, consider admission for close monitoring; intermediate-risk patients may be managed on the oncology ward with nursing q2-4h vitals and labs.
- •Discharge criteria: resolution of metabolic abnormalities (K <5.5, uric acid <7.5, phosphate <4.5, calcium normal), stable renal function, no arrhythmias, and ability to maintain oral hydration. Continue prophylactic allopurinol or febuxostat for the duration of cytoreductive therapy.
Board Review — High Yield
- •Cairo-Bishop criteria, Laboratory TLS requires ≥2 metabolic abnormalities (uric acid ≥8 mg/dL, potassium ≥6.0 mEq/L, phosphate ≥4.5 mg/dL, corrected calcium ≤7 mg/dL) within 3 days before to 7 days after therapy; clinical TLS adds organ dysfunction (AKI, arrhythmia, seizure, death).
- •Rasburicase, The drug of choice for established hyperuricemia in TLS; it rapidly converts uric acid to allantoin. Allopurinol only prevents new uric acid formation and is not effective for existing hyperuricemia.
- •Hyperkalemia management, Emergency treatment: calcium gluconate for cardiac membrane stabilization, then insulin + glucose for intracellular shift. If K >6.0 or ECG changes, treat immediately.
- •Early RRT, Indications in TLS: refractory hyperkalemia, severe hyperphosphatemia, oliguric AKI. The threshold is lower than in other conditions because of rapid electrolyte surges.
- •Spontaneous TLS, Occurs before any therapy, especially in high-burden hematologic malignancies and solid tumors; carries 74% mortality in elderly patients.
- •IDH1/2 mutation, Strong independent risk factor for TLS in AML (OR 4.86); these patients need aggressive prophylaxis.
- •Febuxostat vs allopurinol, Febuxostat may achieve more rapid uric acid control (FLORENCE trial), but meta-analysis shows similar overall efficacy. It is an alternative for allopurinol intolerance.
- •Urine alkalinization, No longer recommended routinely; may increase calcium phosphate precipitation and nephrolithiasis.
- •Obinutuzumab debulking, In CLL, 3 doses of obinutuzumab before venetoclax reduced high-risk TLS status to medium/low in all patients, eliminating mandatory hospitalization.
- •Pseudohyperkalemia, Consider in patients with extreme leukocytosis or thrombocytosis; confirm with plasma potassium to avoid iatrogenic hypokalemia.
Deep Dive — Evidence Details
Definition and Overview
- ▸TLS is a metabolic emergency from rapid cell lysis, most common in hematologic malignancies with high tumor burden.
- ▸Cairo-Bishop criteria distinguish laboratory TLS (biochemical) from clinical TLS (organ dysfunction).
Tumor lysis syndrome (TLS) is an oncologic emergency from rapid release of intracellular contents after massive tumor cell death, causing metabolic derangements that can be fatal if untreated [7]C4. Also called acute TLS, spontaneous TLS (without therapy), laboratory TLS (LTLS) - biochemical abnormalities only, or clinical TLS (CTLS) - with organ dysfunction (AKI, arrhythmia, seizure). Most common in high-proliferative hematologic malignancies like , acute lymphoblastic leukemia, [1]D5, but also solid tumors (e.g., with 59% mortality [7]C4). Seen with targeted agents such as and [4]A1a[5]B2a[8]C4. Classified by : LTLS = ≥2 of hyperuricemia (≥8 mg/dL or 25% increase), hyperkalemia (≥6.0 mEq/L or 25%), hyperphosphatemia (≥4.5 mg/dL or 25%), (≤7 mg/dL or 25% decrease) within 3 days before or 7 days after therapy. CTLS = LTLS plus AKI, arrhythmia, seizure, or death. Metabolic derangements peak 12-72 hours after cytoreduction. Pearl: The earliest laboratory harbinger of TLS is often a rise in serum uric acid or potassium within 12-72 hours of starting therapy; a low threshold for monitoring in high-risk patients (e.g., those with bulky disease, elevated LDH, or pre-existing renal impairment) prevents progression from laboratory to clinical TLS.
Epidemiology and Risk Factors
- ▸TLS incidence is highest in hematologic malignancies with rapid cell turnover; targeted therapies are emerging risk factors.
- ▸IDH1/2 mutation and venetoclax-based therapy are strong independent risk factors in AML.
TLS occurs in 10.5% of hospitalized hematologic neoplasms [17]B3b; in AML induction, 23.1% [14]B3b. Burkitt lymphoma carries high risk [1]D5. Newer targeted therapies increase risk: MCL-1 inhibitor AZD5991 [11]C4, p53-MDM2 inhibitor siremadlin [12]C4, venetoclax (starting dose 20 mg to avoid TLS [13]C4), bispecific T-cell engagers (tarlatamab), CAR-T cells [10]C4[15]A1c, antibody-drug conjugates (gemtuzumab, polatuzumab, brentuximab) [19]D5, and TKIs [9]B2a. Independent risk factors for TLS in AML: male gender (OR 3.28), higher blast percentage (OR 1.03), elevated baseline uric acid (OR 1.01), IDH1/2 mutation (OR 4.86), venetoclax-based therapy (OR 7.52 trend), and lower baseline calcium protective [14]B3b. Median age at TLS diagnosis 56 years, most frequent diagnoses: (18.6%), AML (17.5%), (17.5%) [17]B3b. Rasburicase prophylaxis is strongly protective (OR 0.057) [16]B3b. TLS itself is a major risk factor for AKI (OR 28.81) [16]B3b. Pearl: The strongest predictor of TLS is not just tumor type but the doubling kinetics of cell death; patients with IDH1/2 mutations or receiving venetoclax-based therapy warrant the highest level of monitoring, and rasburicase prophylaxis reduces the odds of TLS by more than 94%.
| Risk Factor | Odds Ratio / Relative Risk | Evidence Level | Source |
|---|---|---|---|
| Male gender | 3.28 | 3b (retrospective cohort) | [14]B3b |
| Higher blast percentage (per unit) | 1.03 | 3b | [14]B3b |
| Elevated baseline uric acid (per unit) | 1.01 | 3b | [14]B3b |
| IDH1/2 mutation | 4.86 | 3b | [14]B3b |
| Venetoclax-based therapy | 7.52 (trend, p=0.072) | 3b | [14]B3b |
| Lower baseline calcium | 0.03 (protective) | 3b | [14]B3b |
| Rasburicase prophylaxis (protective) | 0.057 (95% CI 0.010-0.310) | 3b | [16]B3b |
| TLS → acute kidney injury | 28.81 (95% CI 3.779-219.697) | 3b | [16]B3b |
| High tumor burden (Burkitt, ALL) | Not quantified, but high risk | 5 (expert opinion) | [1]D5[18]D5 |
| TKI therapy | Underreported, definite association | 2a (systematic review) | [9]B2a |
Etiology and Pathophysiology
- ▸Rapid cell lysis releases purines, potassium, phosphate, and calcium, leading to metabolic derangements and AKI.
- ▸Early renal replacement therapy in TLS-associated AKI may improve outcomes.
TLS results from rapid destruction of malignant cells, releasing intracellular contents into bloodstream, overwhelming homeostatic mechanisms [20]C4. This metabolic cascade can progress to acute kidney injury (AKI) requiring renal replacement therapy or ICU admission [20]C4. The key derangements: hyperuricemia from purine metabolism → uric acid nephropathy; hyperkalemia → cardiac arrhythmias; hyperphosphatemia → calcium-phosphate precipitation in renal tubules → AKI; hypocalcemia secondary to hyperphosphatemia → neuromuscular irritability, tetany, seizures. In TLS-associated AKI, early initiation of renal replacement therapy may improve outcomes, hasten recovery, and reduce complications [20]C4. Pearl: In patients with TLS and acute kidney injury, early initiation of renal replacement therapy may improve outcomes; the evidence from a case report suggests that this approach can hasten recovery and reduce complications [20]C4.
Clinical Features and Diagnostic Criteria
- ▸Clinical TLS (organ dysfunction) requires immediate intervention and carries higher mortality.
- ▸Cairo-Bishop criteria define laboratory and clinical TLS, with grading for severity.
Distinguish laboratory TLS (LTLS) from clinical TLS (CTLS). CTLS carries higher mortality and requires urgent intervention. In , TLS occurs with high frequency in high tumor burden [1]D5. In real-world venetoclax for CLL, TLS reported in 6.2% despite risk-adapted prophylaxis [26]C4. Cairo-Bishop criteria: LTLS = ≥2 metabolic abnormalities (uric acid ≥8 mg/dL, K ≥6.0 mEq/L, phosphate ≥4.5 mg/dL, corrected calcium ≤7 mg/dL, or ≥25% change) within 3 days before or 7 days after therapy. CTLS = LTLS plus organ complication: renal impairment (Cr ≥1.5× ULN), arrhythmia, seizure, or death. Grading: Grade 1 (mild), Grade 2 (moderate), Grade 3 (life-threatening), Grade 4 (fatal). Signs/symptoms: hyperkalemia → muscle weakness, ECG changes (peaked T, widened QRS), arrhythmia; hyperphosphatemia → pruritus, AKI; hypocalcemia → perioral paresthesias, Chvostek/Trousseau signs, tetany, seizures; hyperuricemia → nausea, oliguric AKI. ECG: prolonged QT from hypocalcemia; peaked T, widened QRS from hyperkalemia. Pearl: The absence of laboratory TLS does not preclude clinical TLS; monitor for organ dysfunction even when metabolic parameters are near normal, particularly in patients with high tumor burden or rapidly proliferating disease.
| Category | Definition |
|---|---|
| Laboratory TLS | Two or more metabolic abnormalities (uric acid, potassium, phosphate, calcium) within 3 days before or 7 days after therapy |
| Clinical TLS Grade 1 | Laboratory TLS + mild organ dysfunction (e.g., creatinine elevation, brief arrhythmia, seizure) |
| Clinical TLS Grade 2 | Laboratory TLS + organ dysfunction requiring intervention (e.g., arrhythmia treatment, seizure) |
| Clinical TLS Grade 3 | Laboratory TLS + life-threatening organ failure (e.g., dialysis-requiring renal failure, respiratory insufficiency, malignant arrhythmia) |
| Clinical TLS Grade 4 | Laboratory TLS with fatal outcome |
Laboratory Monitoring and Diagnosis
- ▸Cairo-Bishop criteria define thresholds for laboratory TLS; serial monitoring is essential.
- ▸Febuxostat and allopurinol are similar for prophylaxis; rasburicase for clinical TLS.
Diagnosis confirmed by Cairo-Bishop criteria: ≥25% change or absolute thresholds: uric acid ≥8 mg/dL, potassium ≥6.0 mEq/L, phosphate ≥4.5 mg/dL, corrected calcium ≤7 mg/dL within 3 days before or 7 days after therapy. Key labs: uric acid, potassium, phosphate, calcium, creatinine, LDH. Uric acid is central target; FLORENCE trial showed febuxostat 120 mg/day superior to allopurinol for uric acid control (mean AUC 514 vs 708 mg·h/dL, p<0.0001) [28]A1b. Meta-analysis of 6 studies (n=658) found similar response rates and TLS incidence between febuxostat and allopurinol (OR 1.01) [30]A1a. Timing: baseline before therapy, then q6-12h for high-risk patients during first 48-72h, q8-12h for intermediate, daily for low risk. High-risk: Burkitt lymphoma, acute leukemia with high LDH. First-line treatment for laboratory TLS: aggressive IV hydration + xanthine oxidase inhibitor (allopurinol 200-600 mg/day or febuxostat 60-120 mg/day) started 24-48h before chemo [27]A1b[28]A1b. For clinical TLS: low-dose rasburicase (1.5 mg fixed dose) achieves rapid uric acid reduction in ~52% [31]C4. Pearl: The most common cause of missed TLS is failure to monitor labs frequently enough in the first 48 hours after chemotherapy, a rise in phosphate and LDH often precedes uric acid elevation, especially when a xanthine oxidase inhibitor is already on board.
| Parameter | Role in Diagnosis | Typical Threshold (Cairo-Bishop) | Significance of Rise |
|---|---|---|---|
| Uric acid | Primary driver of renal injury | ≥8 mg/dL (or ≥25% change) | Indicates purine catabolism; target for xanthine oxidase inhibitors and rasburicase |
| Potassium | Life-threatening arrhythmia risk | ≥6.0 mEq/L | Rapid rise from cell lysis; requires immediate intervention |
| Phosphate | Calcium-phosphate precipitation | ≥4.5 mg/dL | Rise may precede uric acid elevation; nephrotoxic |
| Calcium | Hypocalcemia from phosphate binding | ≤7 mg/dL (corrected) | Low calcium signals precipitation; monitor for tetany |
| Creatinine | Renal function | ≥1.5× baseline | Reflects tubular injury; may prompt renal replacement therapy |
| LDH | Surrogate of tumor burden | Not diagnostic alone | High levels correlate with TLS risk; a rapid rise is an early warning |
Risk Stratification
- ▸Three-tier risk stratification (low, intermediate, high) guides prophylaxis intensity.
- ▸AML-specific risk factors (IDH1/2 mutation, male sex) may warrant early rasburicase.
Assign risk category using Cairo-Bishop consensus criteria [37]D5 to guide prophylaxis intensity. Three-tier model: low, intermediate, high based on laboratory TLS, tumor proliferation, bulk, and renal function. Low: indolent lymphomas, chronic leukemias without high counts, solid tumors. Intermediate: AML with moderate blast count, , [17]B3b. High: ALL with high WBC, , AML with high blast percentage, high-grade lymphomas. In pediatric ALL, TLS incidence 8.87% [36]B2b; machine learning model identified higher potassium, phosphorus, AST, WBC, and urea as top risk factors (CatBoost AUC 0.832) [36]B2b. AML-specific factors: male gender (OR 3.28), higher blast percentage (OR 1.03), elevated baseline uric acid (OR 1.01), IDH1/2 mutation (OR 4.86), venetoclax trend (OR 7.52) [14]B3b. Presence of laboratory TLS at diagnosis upgrades risk to high [37]D5. TLS occurs in 23.1% of AML induction, with 82% within 72h, severe cases peaking 12-24h [14]B3b. Risk stratification directly guides prophylaxis: low → hydration only; intermediate → hydration + allopurinol/febuxostat; high → upfront rasburicase (controls uric acid in 4h vs 27h with allopurinol [34]A1b). Pearl: In AML, the presence of an IDH1/2 mutation (OR 4.86) or male sex (OR 3.28) should raise the index of suspicion for TLS, even if the Cairo-Bishop criteria classify the patient as intermediate risk; consider early escalation to rasburicase in this subset [14]B3b.
| Risk Category | Key Criteria (from [37]D5) | Common Examples |
|---|---|---|
| Low | No LTLS, low tumor proliferation, small bulk, normal renal function | Indolent lymphomas, chronic leukemias without high counts, solid tumors (except those with high turnover) |
| Intermediate | LTLS not yet present but risk factors present (e.g., moderate proliferation, moderate bulk, or mild renal impairment) | Acute myeloid leukemia (AML) with moderate blast count, diffuse large B-cell lymphoma, multiple myeloma [17]B3b |
| High | LTLS present at diagnosis, high tumor proliferation (e.g., very elevated LDH), bulky disease, or renal impairment | Acute lymphoblastic leukemia (ALL) with high WBC, Burkitt lymphoma, AML with high blast percentage, and other high-grade lymphomas |
Prevention Strategies
- ▸Aggressive IV hydration (2-3 L/m²/day) and pharmacologic uric acid reduction are cornerstones of prevention.
- ▸Rasburicase is preferred for high-risk patients; allopurinol/febuxostat for intermediate risk.
Prevention is the most important measure; established TLS carries high mortality [40]D5. All intermediate/high-risk patients should receive prophylactic interventions before chemotherapy. Hydration: IV crystalloid 2-3 L/m²/day (~200 mL/h in adults), target urine output ≥2 mL/kg/h. Balanced solutions preferred. Xanthine oxidase inhibitors: Allopurinol 300-600 mg/day (or 10 mg/kg/day in children) or febuxostat 40-80 mg/day for intermediate risk. Meta-analysis (6 studies, 658 patients) showed similar response and TLS incidence between febuxostat and allopurinol (OR 1.01) [30]A1a. Febuxostat alternative if allopurinol intolerance. Rasburicase: For high-risk or established hyperuricemia (uric acid ≥7.5 mg/dL) [39]A1c[42]C4. Dose: 0.2 mg/kg/day for up to 5 days, but single doses 1.5-3 mg effective [42]C4. In a phase 2 trial, 83% achieved uric acid <7.5 mg/dL within 24h with single dose [42]C4. Rasburicase associated with lower TLS-associated mortality vs allopurinol (2.1% vs 7.1%, p=0.047) [48]B2b. Urine alkalinization no longer recommended due to risk of calcium phosphate/xanthine precipitation [44]C4. Monitoring: baseline labs then q6-12h during first 24-72h of therapy [47]D5. Patient education: symptoms of TLS, maintain high oral fluid intake, report new symptoms. Pearl: For any patient starting highly cytoreductive therapy, the single most important preventive step is aggressive intravenous hydration aiming for urine output ≥2 mL/kg/h, followed by pharmacologic uric acid reduction, allopurinol for intermediate risk, rasburicase for high risk or established hyperuricemia. Urine alkalinization is no longer recommended.
| Agent | Mechanism | Dose | Indication | Key Evidence |
|---|---|---|---|---|
| Allopurinol | Xanthine oxidase inhibitor | 300-600 mg/day PO (or 10 mg/kg/day in children) | Intermediate-risk TLS; prevention of hyperuricemia | Similar efficacy to febuxostat; risk of xanthine nephrolithiasis [30]A1a[44]C4 |
| Febuxostat | Xanthine oxidase inhibitor | 40-80 mg/day PO | Alternative to allopurinol; allopurinol intolerance | Meta-analysis: OR 1.01 for TLS incidence vs allopurinol [30]A1a |
| Rasburicase | Recombinant urate oxidase | 0.2 mg/kg/day IV (or single dose 1.5-3 mg IV) | High-risk TLS; established hyperuricemia (UA ≥7.5 mg/dL) | 83% response at 24 h with low doses; lower mortality vs allopurinol (2.1% vs 7.1%) [42]C4[48]B2b |
Management of Established TLS
- ▸Clinical TLS requires ICU admission; hyperkalemia is the most immediately life-threatening.
- ▸Rasburicase for hyperuricemia; early renal replacement therapy for severe cases.
When prevention fails or TLS is present at diagnosis, urgent correction of metabolic derangements is needed. All clinical TLS (Cairo-Bishop criteria) requires ICU admission [57]D5. Step 1: Assess severity - Labs: K, phosphate, calcium, uric acid, creatinine, ECG. Exclude pseudohyperkalemia (check plasma K) [60]C4. Step 2: Hyperuricemia - Rasburicase is agent of choice [50]D5[53]C4. Directly cleaves uric acid, rapid reduction. Allopurinol only for prophylaxis, not established TLS [50]D5[53]C4. Aggressive IV hydration (3 L/m²/day in children, 200-250 mL/h in adults) [50]D5[56]D5. Step 3: Hyperkalemia - Emergent treatment if K >6.0 mEq/L or ECG changes: IV calcium gluconate (10% 10-20 mL) for membrane stabilization, then insulin 10U + 50% dextrose 25g IV, plus inhaled beta-agonists (albuterol 10-20 mg). Loops diuretics if renal function adequate, or renal replacement therapy (RRT) [51]D5. Step 4: Hyperphosphatemia/Hypocalcemia - Oral phosphate binders (calcium carbonate, sevelamer) [56]D5. Treat hypocalcemia only if symptomatic (tetany, seizures, prolonged QT) - give calcium gluconate cautiously due to risk of calcium phosphate precipitation. Step 5: Renal replacement therapy - Indications: severe hyperkalemia refractory to medical therapy, severe hyperphosphatemia, acidosis, fluid overload unresponsive to diuretics [56]D5[57]D5. Threshold for RRT lower in TLS [56]D5. CRRT preferred for hemodynamic instability [56]D5. Early nephrology consultation essential. What NOT to do: Do not give calcium for asymptomatic hypocalcemia; do not rely on allopurinol for established hyperuricemia; do not assume all hyperkalemia is real [60]C4. Pearl: Aggressive hydration and rasburicase are the cornerstones of TLS management; early nephrology consultation and a low threshold for RRT are critical in high-risk patients because the ongoing cell breakdown can cause rapid, unpredictable electrolyte surges [56]D5[57]D5 (5,5).
| Derangement | First-Line Intervention | Key Considerations | Evidence Level |
|---|---|---|---|
| Hyperuricemia | Rasburicase (single dose) + IV hydration | Rapid reduction; allopurinol ineffective for existing uric acid | 5 [50]D5[53]C4 |
| Hyperkalemia | Calcium gluconate + insulin/glucose ± albuterol | Check for pseudohyperkalemia; ECG monitoring | 5 [51]D5[60]C4 |
| Hyperphosphatemia | Oral phosphate binders + IV hydration | Avoid calcium if product >60; treat hypocalcemia only if symptomatic | 5 [56]D5 |
| Hypocalcemia | Calcium gluconate (only if symptomatic) | Risk of calcium phosphate precipitation | 5 [56]D5 |
| Acute Kidney Injury | Early RRT (CRRT preferred) | Lower threshold than usual; nephrology consultation | 5 [56]D5[57]D5 |
Special Populations
- ▸Pediatric TLS requires cytoreduction prophase and weight-based dosing.
- ▸In elderly with spontaneous TLS, serum phosphate >6.0 mg/dL is a strong predictor of mortality.
Pediatrics: TLS most common in pediatric and high-grade NHL. In Ethiopian cohort of 50 children, 56% presented with TLS, 24% died during induction [62]B2b. Cytoreduction prophase (low-dose , ) reduces risk. Dosing of allopurinol (10 mg/kg/day divided q8h, max 800 mg/day) and rasburicase per weight. Febuxostat studied but insufficient evidence for superiority [33]D5. CRRT used for clearance [64]D5. Pregnancy: Rare; allopurinol, rasburicase, febuxostat category C. Multidisciplinary management needed. Elderly (≥65 years): Spontaneous TLS with solid tumors has 74% mortality [63]C4. Serum phosphate >6.0 mg/dL at presentation best discriminator of mortality (AUC 0.865; Youden threshold ~6.0 mg/dL) [63]C4. Tumors mostly metastatic, 88% liver involvement [63]C4. Consider early RRT for phosphate >6.0 mg/dL even without overt renal failure. Allopurinol dose-adjust for CrCl <50; rasburicase preferred in renal impairment. Immunocompromised: Increased incidence of high-grade NHL and Burkitt lymphoma. Severe infection before chemo predicts induction mortality (HR 5.45) [62]B2b. Standard prophylaxis with allopurinol or rasburicase; no special dose adjustments. Pearl: In older adults with solid tumors and spontaneous TLS, a serum phosphate >6.0 mg/dL portends a mortality of >70%, consider early renal replacement therapy even before overt renal failure develops.
| Population | Key Differences | Management Modifications |
|---|---|---|
| Pediatrics | High prevalence in Burkitt lymphoma; high mortality in LMIC; weight-based dosing | Allopurinol 10 mg/kg/day; rasburicase 0.15-0.2 mg/kg; consider febuxostat if intolerant; early RRT [33]D5[62]B2b[64]D5 |
| Pregnancy | Rare; teratogenicity concerns; balancing maternal and fetal risk | Use allopurinol with caution (category C); rasburicase category C; consider early delivery if TLS near term; avoid breastfeeding during rasburicase |
| Elderly (≥65 yr) | Spontaneous TLS in solid tumors; high mortality with renal failure and phosphate >6 mg/dL | Adjust allopurinol for renal function; rasburicase preferred in CKD; aggressive monitoring for hyperphosphatemia; early RRT [63]C4 |
| Immunocompromised | Increased risk of hematologic malignancies; higher infection risk | Same prophylaxis; treat infections aggressively; monitor renal function closely [62]B2b |
Prognosis and Outcomes
- ▸TLS prognosis is linked to underlying malignancy; prevention reduces impact.
- ▸With modern prophylaxis, TLS events are rare in venetoclax-based regimens.
Prognosis depends on underlying malignancy and adequacy of prevention. In aggressive lymphomas ( ), TLS is a recognized complication but specific prognostic impact not quantified [1]D5. Modern targeted therapies may carry lower risk: in phase 1 venetoclax + cyclophosphamide + topotecan in pediatric/young adult solid tumors, no TLS events observed [21]C4. In long-term follow-up of ibrutinib + venetoclax in relapsed/refractory , no TLS occurred [23]C4. These findings suggest that with appropriate risk stratification and prophylaxis, TLS can be effectively prevented, minimizing impact on overall prognosis. Key is early identification of at-risk patients and adherence to prophylaxis protocols. Pearl: In patients receiving venetoclax‑based therapy, TLS events are exceedingly rare when standard prophylaxis is implemented [21]C4[23]C4; this underscores the importance of risk‑adapted monitoring rather than assuming all patients are at equivalent risk.
| Factor | Association with TLS |
|---|---|
| High tumor burden in Burkitt lymphoma | Established risk factor for TLS [1]D5 |
| Use of venetoclax‑based regimens | Low TLS incidence in clinical trials [21]C4[23]C4 |
Guidelines and Key Evidence
- ▸Obinutuzumab debulking before venetoclax eliminates high-risk TLS status.
- ▸Guidelines recommend risk-adapted prophylaxis: hydration, allopurinol/febuxostat, or rasburicase.
Several international organizations have issued formal recommendations. Key guidelines: ERN-EuroBloodNet (Burkitt lymphoma) [1]D5 - risk-adapted therapy; KDIGO Controversies Conference on Onco-Nephrology [66]A1c - identifies TLS as major cause of AKI; SFGM-TC (CAR-T cells) [15]A1c - recognizes TLS as specific complication; Japanese Society of Clinical Oncology [39]A1c - recommends febuxostat for hyperuricemia, rasburicase for high-risk; Argentine Society of Pediatrics [40]D5 - emphasizes prevention with hydration. Landmark trials: MURANO (venetoclax-rituximab for CLL) - grade 3-4 TLS in 3.1% despite prophylaxis [71]A1b. CRISTALLO (first-line CLL) - obinutuzumab debulking before venetoclax eliminated high-risk status in all patients, 0 mandatory hospitalizations for TLS monitoring [67]A1b. CAPTIVATE (first-line CLL) - ibrutinib lead-in shifted 90% of high-risk patients to medium/low [69]A1b. SYMPATICO (MCL) - only 1 laboratory TLS [68]B2b. Controversy: routine use of rasburicase vs allopurinol - Japanese guidelines favor rasburicase for high-risk [39]A1c while Argentine guidelines recommend hydration without specific agent [40]D5. Clinical prediction tools embedded in venetoclax prescribing information (validated in CRISTALLO and CAPTIVATE). Pearl: The most practice-changing evidence from the CRISTALLO trial is that obinutuzumab debulking before venetoclax can eliminate high-risk TLS status entirely, converting all high-risk patients to medium or low risk and eliminating mandatory hospitalization, a strategy that should be adopted whenever feasible [67]A1b.
| Guideline / Organization | Year | Key Recommendation(s) |
|---|---|---|
| ERN-EuroBloodNet (Burkitt lymphoma) [1]D5 | 2025 | Specific recommendations for identification and management of TLS in high-tumor-burden Burkitt lymphoma; emphasize CNS-oriented therapy and risk-adapted first-line therapy. |
| KDIGO Controversies Conference on Onco-Nephrology [66]A1c | 2020 | Identifies TLS as a major cause of AKI in hematological malignancies; calls for multidisciplinary collaboration and research on optimal prophylaxis. |
| SFGM-TC (CAR-T cells) [15]A1c | 2021 | Recognizes tumoral lysis syndrome as a specific complication after CAR-T infusion; recommends monitoring and management strategies analogous to conventional chemotherapy-induced TLS. |
| Japanese Society of Clinical Oncology [39]A1c | 2023 | Recommends febuxostat for avoiding hyperuricemia induced by TLS; preventive rasburicase is recommended in high-risk cases. |
| Argentine Society of Pediatrics [40]D5 | 2020 | Emphasizes prevention as the most important therapeutic measure; recommends intravenous hydration and measures to correct metabolic alterations. |
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine use of rasburicase vs. allopurinol | Japanese guidelines [39]A1c: rasburicase for high-risk; febuxostat as alternative | Argentine pediatric guidelines [40]D5: prevention with hydration and correction of metabolic abnormalities, no specific agent recommendation | Expert opinion | Cost and availability drive choice; rasburicase reserved for high-risk or established TLS with hyperuricemia. |
| TLS risk assessment in CAR-T therapy | SFGM-TC [15]A1c includes TLS as a recognized complication; recommends monitoring similar to standard chemotherapy | KDIGO [66]A1c does not specifically address CAR-T-related TLS | Emerging evidence | Patients receiving CAR-T with high tumor burden should be managed with same prevention protocols as conventional high-risk TLS. |
References
- [1]
Ribrag V, Bron D, Rymkiewicz G et al.. “Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet.” The Lancet. Haematology (2025). PMID: 39909657 ↗
L5GUIDELINECited in: Definition and Overview, Epidemiology and Risk Factors, Clinical Features and Diagnostic Criteria, Prognosis and Outcomes, Guidelines and Key Evidence - [2]
El-Tanani M, Rabbani SA, Patni MA et al.. “Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis.” Vaccines (2025). PMID: 41150456 ↗
L1SR_OBSCited in: Definition and Overview - [3]
Arjeini Y, Khalili Dermani S, Sadeh S et al.. “Oncolytic viruses in brain cancer therapy: advances, challenges, and clinical trial outcomes.” Immunotherapy (2026). PMID: 42077101 ↗
L5TRIAL_NONRANDOMCited in: Definition and Overview, Clinical Features and Diagnostic Criteria, Prognosis and Outcomes - [4]
Yao P, Zhang J, Wang X et al.. “Evidence-based investigation of the efficacy and safety of venetoclax-containing regimens versus chemoimmunotherapy in chronic lymphocytic leukemia.” Naunyn-Schmiedeberg's archives of pharmacology (2025). PMID: 39992421 ↗
L1SR_OBSCited in: Definition and Overview, Clinical Features and Diagnostic Criteria, Prognosis and Outcomes - [5]
Wu TL, Chen CK, Chao CM et al.. “Risk assessment of venetoclax-associated adverse events: a meta-analysis approach.” Expert opinion on drug safety (2025). PMID: 39829042 ↗
L2SR_OBSCited in: Definition and Overview, Risk Stratification - [6]
Burroni AG, Capurro N, Rongioletti F et al.. “Diffuse Melanosis Cutis as the First Sign of Recurrence of Low-Risk Melanoma: Case Report and Systematic Review.” Dermatology practical & conceptual (2024). PMID: 38364426 ↗
L4SR_OBSCited in: Definition and Overview - [7]
de Matos UMA, Tan WY, Forbes V. “Tumor Lysis Syndrome in Colorectal Cancer-A Systematic Review of Literature.” Journal of gastrointestinal cancer (2026). PMID: 41893976 ↗
L4SR_OBSCited in: Definition and Overview, Special Populations - [8]
Kou K, Zhou Q, Du L et al.. “Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.” Frontiers in immunology (2025). PMID: 40918110 ↗
L4CASE_REPORTCited in: Definition and Overview - [9]
Salter B, Burns I, Fuller K et al.. “Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review.” European journal of haematology (2022). PMID: 35531791 ↗
L2SR_OBSCited in: Epidemiology and Risk Factors - [10]
Minocha M, Thompson CG, Murphy A et al.. “Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.” Clinical pharmacokinetics (2024). PMID: 39589690 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors - [11]
Desai P, Lonial S, Cashen A et al.. “A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39167622 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Clinical Features and Diagnostic Criteria - [12]
Stein EM, DeAngelo DJ, Chromik J et al.. “Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34862243 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors - [13]
Portell CA, Wages NA, Kahl BS et al.. “Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.” Blood advances (2022). PMID: 34700344 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology and Risk Factors - [14]
Yuan F, Zhao X, Lin X et al.. “Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective study.” Leukemia research (2026). PMID: 41996825 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Risk Stratification - [15]
Pochon C, Courbon C, Bay JO et al.. “[Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)].” Bulletin du cancer (2021). PMID: 34802718 ↗
L1GUIDELINECited in: Epidemiology and Risk Factors, Guidelines and Key Evidence - [16]
Kesici S, Nakip OS, Aksu T et al.. “Leukapheresis, rasburicase, and acute complications of hyperleukocytosis in pediatric leukemia: A retrospective cohort study.” Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (2026). PMID: 42247950 ↗
L3COHORTCited in: Epidemiology and Risk Factors - [17]
Calvache ET, Calvache ADT, Weber CS. “Tumor lysis syndrome in hematological inpatients, experience from a university hospital in Brazil: A retrospective cohort study.” Hematology, transfusion and cell therapy (2023). PMID: 37085347 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Laboratory Monitoring and Diagnosis, Risk Stratification, Prevention Strategies - [18]
Molyneux K, Beck-Esmay J, Koyfman A et al.. “High risk and low incidence diseases: Tumor lysis syndrome.” The American journal of emergency medicine (2025). PMID: 40939243 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [19]
Markides DM, Hita AG, Merlin J et al.. “Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.” Annals of emergency medicine (2024). PMID: 39641680 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [20]
ELJack A, El Abdallah M, Al-Banaa K et al.. “A New Challenging Strategy in the Prevention and Management of Tumor Lysis Syndrome in Patients with Chemo-Sensitive Hematological Malignancies.” Case reports in oncological medicine (2019). PMID: 31236296 ↗
L4CASE_REPORTCited in: Etiology and Pathophysiology - [21]
Morgenstern DA, Barone G, Corradini N et al.. “Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study.” Pediatric blood & cancer (2026). PMID: 41823176 ↗
L4TRIAL_NONRANDOMCited in: Clinical Features and Diagnostic Criteria, Special Populations, Prognosis and Outcomes - [22]
Ji D, Fu W, Liu Y et al.. “First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.” BMC medicine (2026). PMID: 41721376 ↗
L4TRIAL_NONRANDOMCited in: Clinical Features and Diagnostic Criteria, Prognosis and Outcomes - [23]
Goto H, Ito S, Kizaki M et al.. “Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.” International journal of clinical oncology (2025). PMID: 40897939 ↗
L4TRIAL_NONRANDOMCited in: Clinical Features and Diagnostic Criteria, Prognosis and Outcomes - [24]
Luskin MR, Shimony S, Keating J et al.. “Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.” Blood advances (2025). PMID: 39546748 ↗
L4TRIAL_NONRANDOMCited in: Clinical Features and Diagnostic Criteria - [25]
Wang M, Robak T, Maddocks KJ et al.. “Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.” Blood advances (2024). PMID: 38781315 ↗
L4TRIAL_NONRANDOMCited in: Clinical Features and Diagnostic Criteria - [26]
Ito T, Kamimura T, Kiguchi T et al.. “Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.” International journal of hematology (2024). PMID: 39167348 ↗
L4TRIAL_NONRANDOMCited in: Clinical Features and Diagnostic Criteria - [27]
Tamura K, Kawai Y, Kiguchi T et al.. “Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.” International journal of clinical oncology (2016). PMID: 27017611 ↗
L1RCTCited in: Laboratory Monitoring and Diagnosis - [28]
Spina M, Nagy Z, Ribera JM et al.. “FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26216382 ↗
L1RCTCited in: Laboratory Monitoring and Diagnosis - [29]
Takai M, Yamauchi T, Ookura M et al.. “Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.” Anticancer research (2014). PMID: 25503162 ↗
L4COHORTCited in: Laboratory Monitoring and Diagnosis - [30]
Bellos I, Kontzoglou K, Psyrri A et al.. “Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis.” Journal of clinical pharmacy and therapeutics (2019). PMID: 30972811 ↗
L1SR_OBSCited in: Laboratory Monitoring and Diagnosis, Prevention Strategies - [31]
Majumdar S, Sharma N, Sengar M et al.. “A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.” Leukemia & lymphoma (2023). PMID: 36891578 ↗
L4TRIAL_NONRANDOMCited in: Laboratory Monitoring and Diagnosis - [32]
Schlesinger N, Kaufmann D. “Updates in uricase therapy for gout.” Current opinion in rheumatology (2025). PMID: 40916989 ↗
L5REVIEW_NARRATIVECited in: Laboratory Monitoring and Diagnosis - [33]
Faghihi T, Assadi F. “Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report.” Clinical therapeutics (2025). PMID: 40024815 ↗
L5REVIEW_NARRATIVECited in: Laboratory Monitoring and Diagnosis, Special Populations - [34]
Cortes J, Moore JO, Maziarz RT et al.. “Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20713865 ↗
L1RCTCited in: Risk Stratification - [35]
Lin TS, Ruppert AS, Johnson AJ et al.. “Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19826119 ↗
L4TRIAL_NONRANDOMCited in: Risk Stratification - [36]
Xiao Y, Xiao L, Zhang Y et al.. “Prediction of tumor lysis syndrome in childhood acute lymphoblastic leukemia based on machine learning models: a retrospective study.” Frontiers in oncology (2024). PMID: 38515564 ↗
L2COHORTCited in: Risk Stratification - [37]
Cairo MS, Coiffier B, Reiter A et al.. “Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.” British journal of haematology (2010). PMID: 20331465 ↗
L5REVIEW_NARRATIVECited in: Risk Stratification - [38]
Rahmani B, Patel S, Seyam O et al.. “Current understanding of tumor lysis syndrome.” Hematological oncology (2019). PMID: 31461568 ↗
L5REVIEW_NARRATIVECited in: Risk Stratification - [39]
Ando Y, Nishiyama H, Shimodaira H et al.. “Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.” International journal of clinical oncology (2023). PMID: 37453935 ↗
L1GUIDELINECited in: Prevention Strategies, Guidelines and Key Evidence - [40]
. “[Recommendations for tumor lysis syndrome management].” Archivos argentinos de pediatria (2020). PMID: 32199069 ↗
L5GUIDELINECited in: Prevention Strategies, Guidelines and Key Evidence - [41]
Asada N, Ando J, Takada S et al.. “Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.” Japanese journal of clinical oncology (2023). PMID: 37017320 ↗
L4TRIAL_NONRANDOMCited in: Prevention Strategies - [42]
Vachhani P, Baron J, Freyer CW et al.. “A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.” Leukemia research (2021). PMID: 33957371 ↗
L4TRIAL_NONRANDOMCited in: Prevention Strategies - [43]
Conard R, Trivedi C, Page W. “Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.” Seminars in oncology (2026). PMID: 42335755 ↗
L4CASE_REPORTCited in: Prevention Strategies - [44]
Goswami S, Hanson AE, Rajadhyaksha E et al.. “Allopurinol use leading to xanthine nephrolithiasis in pediatric tumor lysis syndrome: a case series.” Pediatric nephrology (Berlin, Germany) (2024). PMID: 38842722 ↗
L4CASE_REPORTCited in: Prevention Strategies - [45]
Gartenberg A, Winkel M, Leonard N. “Spontaneous tumor lysis syndrome in a patient with chronic myeloid leukemia treated successfully with allopurinol.” The American journal of emergency medicine (2023). PMID: 38007380 ↗
L4CASE_REPORTCited in: Prevention Strategies - [46]
Cailleteau A, Touzeau C, Jamet B et al.. “Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature.” Clinical and translational radiation oncology (2021). PMID: 34816023 ↗
L4CASE_REPORTCited in: Prevention Strategies - [47]
Fischer K, Al-Sawaf O, Hallek M. “Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.” Hematology. American Society of Hematology. Education Program (2020). PMID: 33275717 ↗
L5CASE_REPORTCited in: Prevention Strategies - [48]
Cairo MS, Gallagher JR, Barnes Y et al.. “Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 41225055 ↗
L2OTHERCited in: Prevention Strategies - [49]
Karp JE, Blackford A, Smith BD et al.. “Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.” Leukemia research (2009). PMID: 19962759 ↗
L4TRIAL_NONRANDOMCited in: Management of Established TLS - [50]
Howard SC, Avagyan A, Workeneh B et al.. “Tumour lysis syndrome.” Nature reviews. Disease primers (2024). PMID: 39174582 ↗
L5REVIEW_NARRATIVECited in: Management of Established TLS - [51]
Dubbs SB. “Rapid Fire: Tumor Lysis Syndrome.” Emergency medicine clinics of North America (2018). PMID: 30037438 ↗
L5CASE_REPORTCited in: Management of Established TLS - [52]
Ignaszewski M, Kohlitz P. “Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.” The American journal of emergency medicine (2017). PMID: 28587951 ↗
L4CASE_REPORTCited in: Management of Established TLS - [53]
Bercovitz RS, Greffe BS, Hunger SP. “Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma.” Current opinion in pediatrics (2010). PMID: 19926992 ↗
L4CASE_REPORTCited in: Management of Established TLS - [54]
Cavalli R, Buffon RB, de Souza M et al.. “Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?” Dermatology (Basel, Switzerland) (2012). PMID: 22516868 ↗
L4CASE_REPORTCited in: Management of Established TLS - [55]
Abd El-Fattah EE. “Tumor lysis syndrome promotes cancer chemoresistance and relapse through AMPK inhibition.” International immunopharmacology (2022). PMID: 36527883 ↗
L5REVIEW_NARRATIVECited in: Management of Established TLS - [56]
Matuszkiewicz-Rowinska J, Malyszko J. “Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress.” Kidney & blood pressure research (2020). PMID: 32998135 ↗
L5REVIEW_NARRATIVECited in: Management of Established TLS - [57]
Burghi G, Berrutti D, Manzanares W. “[Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare].” Medicina intensiva (2010). PMID: 21112673 ↗
L5REVIEW_NARRATIVECited in: Management of Established TLS - [58]
Shafie M, Teymouri A, Parsa S et al.. “Spontaneous tumor lysis syndrome in adrenal adenocarcinoma: a case report and review of the literature.” Journal of medical case reports (2022). PMID: 35139902 ↗
L4CASE_REPORTCited in: Management of Established TLS - [59]
Dey A, Wyrebek R, Torres L et al.. “Tumor lysis syndrome in premature infant prompting early resection of a large sacrococcygeal teratoma: a case report.” BMC pediatrics (2023). PMID: 37660010 ↗
L4CASE_REPORTCited in: Management of Established TLS - [60]
Huang YC, Huang FL, Tsai SF et al.. “Pseudohyperkalemia accompanying actual hyperphosphatemia and hypocalcemia in an adolescent with T-lymphoblastic lymphoma.” Clinical biochemistry (2021). PMID: 34922929 ↗
L4CASE_REPORTCited in: Management of Established TLS - [61]
Manda S, Anz BM, Benton C et al.. “A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.” Hematological oncology (2024). PMID: 38711253 ↗
L2TRIAL_NONRANDOMCited in: Special Populations - [62]
Nigusie M, Adam H, Weitzman S et al.. “Early treatment-related morbidity and mortality of children with non-Hodgkin's lymphoma treated at Tikur Anbesa Specialized Hospital with modified ALCL protocol: prospective cohort study.” BMC cancer (2025). PMID: 41029278 ↗
L2COHORTCited in: Special Populations - [63]
Pettit SM, Liu N. “Global evidence and clinical implications of spontaneous tumor lysis syndrome in older adults with solid tumors: a systematic review of reported cases.” Japanese journal of clinical oncology (2026). PMID: 41996397 ↗
L4SR_OBSCited in: Special Populations - [64]
Chanchlani R, Askenazi D, Bayrakci B et al.. “Extracorporeal pediatric renal replacement therapy: diversifying application beyond kidney failure.” Pediatric nephrology (Berlin, Germany) (2024). PMID: 39375217 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [65]
Posado-Domínguez L, Figuero-Pérez L, Olivares-Hernández A et al.. “Paraneoplastic leukocytosis secondary to carcinosarcoma: a report of two cases and literature review.” Chinese clinical oncology (2024). PMID: 38859609 ↗
L4CASE_REPORTCited in: Special Populations - [66]
Małyszko J, Bamias A, Danesh FR et al.. “KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation.” Kidney international (2020). PMID: 33276867 ↗
L1GUIDELINECited in: Guidelines and Key Evidence - [67]
Sharman JP, Laurenti L, Ferrant E et al.. “Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.” Blood (2026). PMID: 41770817 ↗
L1RCTCited in: Guidelines and Key Evidence - [68]
Wang M, Ramchandren R, Chen R et al.. “Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.” Journal of hematology & oncology (2021). PMID: 34717692 ↗
L2RCTCited in: Guidelines and Key Evidence - [69]
Wierda WG, Allan JN, Siddiqi T et al.. “Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34618601 ↗
L1RCTCited in: Guidelines and Key Evidence - [70]
Litzow MR, Wang XV, Carroll MP et al.. “A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.” American journal of hematology (2018). PMID: 30370956 ↗
L1RCTCited in: Guidelines and Key Evidence - [71]
Seymour JF, Kipps TJ, Eichhorst B et al.. “Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.” The New England journal of medicine (2018). PMID: 29562156 ↗
L1RCTCited in: Guidelines and Key Evidence